2015 Speakers

Keynote Speaker

Ilan GanotIlan Ganot

CEO and Founder of Solid Biosciences; Former JPMorgan Chase Investment Banker

Ilan Ganot is Founder, CEO and member of the board of directors for Solid Biosciences. Prior to starting Solid, Ganot was an investment banker at JPMorgan Chase in London, specializing in hedge funds driven equities business for the firm. Ilan also worked at Nomura Securities in London, Hong Kong and New York and Lehman Brothers in Europe.

Ganot embarked on a banking career after practicing law at leading Israeli firm, Haim Zadok & Co., where his focus was private equity law and mergers and acquisitions. He was a captain in the Israel Defense Forces. He received his MBA from London Business school and holds law and business degrees from the IDC in Herzliya, Israel.

Join us to hear the inspiring story of a successful investment banker whose son, Eytani (which means “solid” in Hebrew), was born with Duchenne’s muscular dystrophy (DMD), and the decision he made to spend his life trying to cure DMD. Ganot gave up his career to start a company to help find a treatment/cure and help for his son and others with DMD. Solid is using a gene delivery technology and animal models from the University of Missouri to develop novel therapies. (Solid is also looking at anti-inflammatory/NFKB approaches in collaboration with Pfizer). You’ll also learn innovative ways Ganot’s team is approaching management of DMD and be able to meet Mizzou scientists and entrepreneurs involved with this innovative company.

Solid Biosciences

Panel Speakers

The panel discussion topics will include:

  • “The Role of Academic Research in Industry and Economic Growth, New Models For Success”
  • “The VC/Investor View of Technology”
  • “Elements of a Successful Start-Up”
  • “Translational Research: Bridging the Gap Between Early & Applied Research in Start-Ups”
  • “What Is ‘De-Risking’ In Innovation?”
  • “Business Development for Early Start-Ups: How To Make Connections”

Panel members include:

Ilan Ganot

CEO and Founder of Solid Biosciences; Former JPMorgan Chase Investment Banker (see bio above)


Alfred BotchwayAlfred Botchway

President of Xenometrics and The Safety Pharmacology Society; Pipeline Graduate

Alfred Botchway, Ph.D., DSP is President and Founder of Xenometrics, LLC, a non-clinical contract research service provider. Xenometrics performs research studies designed to; investigate pharmacokinetic/pharmacodynamics profiles, minimize potential toxic and/or undesirable effects of agrochemical, biotechnological and pharmaceutical products on physiological functions prior to administration to the intended population. Alfred has past experience with academic research, a major pharmaceutical company, a contract laboratory, teaching medical school students, developing cost effective methods and managing multimillion dollar revenue streams.

Alfred’s experience includes extensive research in safety pharmacology; he has monitored and conducted numerous studies on behalf of many companies. He has given countless scientific presentations and has been profoundly involved with studies in support of Investigational New Drug (IND) applications. Furthermore, Alfred has served as a reviewer for multiple scientific manuscripts for highly esteemed international scientific journals. He is an active member of several international scholastic professional scientific organizations including the British Physiological Society and Society of Toxicology. Alfred currently serves on the board of directors of the International Safety Pharmacology Society as the society’s President. In addition to his scientific endeavors, he also serves on the State of Kansas’s Council of Economic Advisors. Alfred graduated from Pipeline (an Entrepreneurial Immersion Program), and was elected the first President of the Alumni, and continues to serve as a Board member for Pipeline.

Alfred holds a BSc and an MSc in Biomedical Science from the University of Kingston, Surrey, UK and the North East College of Technology, Surrey, UK, respectively. By virtue of his masters (hematology major), he developed a keen interest in cardiovascular physiology. Subsequent to a special interest and research in electrophysiological changes associated with regression of left ventricular hypertrophy, Alfred was awarded a Ph.D. from the Imperial College of Science, Technology and Medicine, London, UK. Dr. Alfred Botchway also holds a Diplomate in Safety Pharmacology further enhancing his scientific knowledge.

Xenometrics: Experience | Rapid Turnaround | Flexibility


Fred HausheerFred Hausheer, M.D., FACP

Entrepreneur/Inventor & Founder/Former CEO of BioNumerik Pharmaceuticals

Dr. Frederick Hausheer, is the founder and former Chairman, Chief Executive Officer of BioNumerik Pharmaceuticals, Inc., based in San Antonio, Texas. He has been involved for more than 25 years in global oncology drug development and drug discovery and has developed two self originated drugs from laboratory through Phase III development for less than $100 MM each, and has participated in drug development on many cancer therapeutic agents.

He completed his graduate training in Physiology and Biophysics under a full academic scholarship at the University of Illinois-Champagne, graduated from the University of Missouri School of Medicine in less than three years with Honors, completed his residency in Internal Medicine at MU, and completed his Fellowship in Medical Oncology in two years with a focus on investigational new drug development and pharmacology at Johns Hopkins. He received two American Cancer Society Clinical Development Awards and the National Scientific Research Award from the NCI while at Johns Hopkins. He currently holds adjunct professorships at MU in Internal Medicine and Oncology, and in Medical Oncology at Johns Hopkins.

He has been involved for over 25 years in merging the physics-based computer simulations of molecular interactions and properties by the use of quantum and statistical mechanics using high performance computing and merging this with experimental design for drug discovery to facilitate translational medicine. For this work he was awarded the Smithsonian Institution and ComputerWorld in Medicine. His therapeutic areas of interest include DNA targeting agents, oxidative stress, signal transduction inhibitors, and epigenetics.

Dr. Hausheer has over 200 publications, abstracts and book chapters, and is an inventor or co-inventor on more than 400 issued/allowed United States and international Patents. He has served as a board member/adviser to JP Morgan Chase, the Whittaker Institute for BioMedical Engineering at Johns Hopkins, the Institutional Review Board of the National Cancer Institute and he advises many pharmaceutical companies on drug discovery and development.


Joseph HedrickJoseph Hedrick, Ph.D.

Venture Leader T1D Disease Interception Accelerator; Janssen Research & Development

Joseph Hedrick, Ph.D., Venture Leader T1D Disease Interception Accelerator (Janssen Research and Development, a Johnson & Johnson Company), will share how Johnson & Johnson is interfacing with academia and start-ups. He will also talk about J&J’s disease interception/management focus areas. It will be good for investors and entrepreneurs (start-ups) to hear how J&J is organizing to find and develop novel therapies.

Hedrick currently leads Janssen’s effort in T1D interception and brings over 20 years of experience in both industry and non-profit drug discovery research in immunology and diabetes. He previously served as a Scientific Director in Janssen’s Cardiovascular and Metabolic therapy area where he was responsible for initiating innovative new target programs. He also served as Janssen’s steering committee representative for the Accelerated Medicines Partnership with the NIH. Prior to joining Janssen, Hedrick spent more than two years as Senior Director for Cure and Prevent Therapies at JDRF, the largest non-profit T1D research organization. While at JDRF, he oversaw both the immune and beta cell replacement efforts and was responsible for developing and implementing JDRF’s T1D interception and biomarker strategies. Prior to JDRF, he led Schering-Plough’s diabetes pre-lead op drug discovery and subsequently served as the Director of Biologics Strategy for diabetes and cardiovascular disease at Merck & Co. Hedrick received his Ph.D. from the University of California, San Diego and San Diego State University, where he studied T cell development and the interaction of Epstein-Barr virus with cells of the immune system. His postdoctoral training was with Dr. Albert Zlotnik at the DNAX Research Institute in Palo Alto, Calif., where he identified and characterized a number chemokines, proteins that control movement of immune cells. Dr. Hedrick is the author of more than 50 peer-reviewed scientific articles, several book chapters and is an inventor on more than 30 patents and patent applications.


John WestwickJohn K. Westwick, Ph.D.

CEO of Resonant Therapeutics, Inc. & Entrepreneur-In-Residence (Life Sciences), Mercury Fund

John K. Westwick, Ph.D. & CEO of Resonant Therapeutics, Inc, a biotech start-up creating breakthrough therapies for cancer treatment. He is also Entrepreneur-In-Residence, Life Sciences with Mercury Fund, where he is actively seeking new oncology therapies and technologies. Westwick’s scientific and biotech career spans 30 years, with a constant focus on defining the cellular mechanisms of cancer, inflammatory and metabolic disease and translating this knowledge into improved therapeutics. He has contributed to multiple drug development programs that are either marketed, or in development, and has published more than 60 scientific articles and patents.

Previously, Dr. Westwick was President & CEO of Odyssey Thera, a privately held company that developed breakthrough technologies for cell systems biology. Technologies developed at Odyssey are now marketed worldwide by ThermoFisher. Prior to Odyssey, Dr. Westwick held scientific leadership positions at Celgene Corp. and Signal Pharmaceuticals. He holds a B.A. degree in Biology from the University of California at San Diego, and a Ph.D. in Molecular Pathology from the UC San Diego School of Medicine. Post-doctoral studies in Medicine and Pharmacology were performed at the University of North Carolina, Chapel Hill School of Medicine, and he was subsequently named the Lineberger Cancer Center Fellow at the UNC Comprehensive Cancer Center. Outside of Mercury, Dr. Westwick is an adviser for several biotech start-ups and serves on the board of directors of Vala Sciences, Inc. and Visionary Pharmaceuticals, Inc.

Resonant Therapeutics Mercury Fund


David AndersonDavid Anderson, Ph.D.

Entrepreneur in Residence, University of Missouri, Office of Technology Management and Industry Relations

Moderator

David Anderson, Ph.D. has deep expertise in target-based drug discovery/ development and personalized molecular diagnostics in inflammation and oncology. He built and managed innovative drug discovery and development companies, including Signal Pharmaceuticals from start-up (focused on kinases and other gene-regulating targets) to acquisition by Celgene Corporation and Proprius Pharmaceuticals from start-up (focused on Personalized Medicine and Molecular Diagnostics) to acquisition by Cypress Bioscience.

Anderson has held senior positions at Ignyta (CSO/ VP Cancer Biology), Eclipse Therapeutics (VP R&D acquired by Bionomics), Proprius Pharmaceuticals, (CSO) Celgene Corporation (CSO/Senior VP), Johnson & Johnson (Senior Director Immunotherapy/ Inflammation Drug Discovery), and Monsanto/ Searle (Senior Group Leader). He was leader or member of teams responsible for development of five approved drugs (Procrit®, Leustatin®, and Revlimid® for hematology/oncology indications, Zubrin® for veterinary arthritis use, and Surfaxin® for respiratory distress syndrome), two NDAs, and nine INDs, and two Personalized Dx products (AVISE-PG® & AVISE-MCV®) for rheumatoid arthritis.

He has served as a consultant for numerous companies (Johnson & Johnson, Celgene, Santarus/Salix, Adventrx, aTyr Pharma), VC and investment firms (Kleiner Perkins Caufield & Byers, Venrock Ventures, CID Equity Partners & Clarian Health, City Hill Ventures) and as an SAB member (Visionary Pharmaceuticals, Capella Therapeutics).

Anderson received a Ph.D. from The University of Missouri in Medical Microbiology and Immunology and has held academic positions at the University of Colorado Health Sciences Center, The Scripps Research Institution and Graceland University. He has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti-inflammatory/ immunomodulatory and cancer drugs, and has refereed articles for peer-reviewed journals including Science, The Journal of Rheumatology and The Journal of Pharmacology and Experimental Therapeutics. He has an outstanding record of scientific publications and presentations (32 peer reviewed publications and over 50 presentations/abstracts) and has received a number of research awards and five (5) patents for his innovative research.

Next Big Thing Speakers

Robert A. BonelliRobert A. Bonelli, Ph.D.

Co-Founder, President & Chief Executive Officer Adsorbed Natural Gas Products, Inc. (ANGP)

Robert Allen Bonelli, Co-Founder and Chief Executive Officer of ANGP, is a 39-year veteran business executive who has led the development of a number of organizations. A degreed electrical engineer (B.S. E.E. Polytechnic Institute of New York University), who after starting his career in engineering then transitioned into the financial industry where he became known for strategic planning, corporate development and executive leadership in building companies. Bonelli is an author of both non-fiction and fiction works. He is a “regular” on talk radio stations and has appeared on Fox News, Fox Business, CNBC and Bloomberg Television.

Bonelli’s career highlights include: (1) his work on the material science aspects of the Poseidon missile’s guidance system, while working for a precision science engineering firm under contract with the U.S. Navy (during his full-time studies at the Polytechnic); (2) his work on the development of the first field engineering/marketing interface at Digital Equipment Corporation; (3) his work to change Regulation Y of the Federal Bank Holding Act, which permitted discount brokerage; (4) his efforts to plan and execute the first interstate banking acquisition between New Jersey and Pennsylvania; (5) his launch of New Jersey’s first bank-owned insurance brokerage; (6) his efforts to convert a 68 year-old Wall Street partnership to a C-corporation, while increasing revenues from $67 million to over $120 million in four years; (7) while at Ernst & Co.; his management of the Ernst Bank Equity Fund, L.P., resulting in seven years of NET 30 percent annual returns; and (8) his leadership in the restructuring of Northeast Securities, Inc., from a retail brokerage to a diversified financial services company. Currently, Bonelli is leading the effort at ANGP to commercialize on-board low-pressure ANG technology.


Hao LiHao Li, Ph.D.

Professor of Engineering, University of Missouri, and President and Co-Founder of Nanova, Inc.

Dr. Li is President of Nanova Inc., a biotech start-up based in Columbia, Mo. He is trained as a materials scientist with a bachelor’s and master’s degree from Xi’an Jiaotong University and a Ph.D. from Stevens Institute of Technology. He obtained postdoctoral training from Brown University in nanotechnology. Inspired by the fact that both bone and teeth are composites containing calcium phosphate nanofibers, Li first applied nanocomposite technology in the field of dentistry and orthopedics to develop products with improved strength and biological properties. This technology—developed at MU and funded by both National Science Foundation (NSF) and National Institute of Health—was licensed by Nanova, Inc., and led to an investment of more than $7 million in 2013. The FDA approved a flowable dental composites filler based on this technology in 2015.

Dr. Li and his colleagues at Nanova are also developing other technologies: a multiple function dental plasma brush for more durable restoration, a coronary stent with reduced restenosis and thrombosis and novel antimicrobial small compounds with a novel anti-virulence mechanism, which disarm bacteria instead of killing them. Notably, the antimicrobial compounds impose less selective pressure for the bacteria and may not lead to drug resistance. Some of these technologies are currently backed by venture capital investments. With both entrepreneurial and academic experience, Dr. Li is connecting academia, industry and financial firms to positively impact society.

Nanova is currently developing innovative solutions that may improve the healthcare of patients, particularly in the areas of medical devices, pharmaceuticals and environmental technologies. Strategically, Nanova brings scientists and engineers, university professors, medical doctors, dentists, entrepreneurs, and businessmen together to initiate and develop disruptive technologies and eventually make them available for the benefits of patients and the general public.